Jump to content

Patrick A. Baeuerle

From Wikipedia, the free encyclopedia
(Redirected from Patrick Baeuerle)
Patrick A. Baeuerle
Born
Patrick Alexander Baeuerle

(1957-11-24) November 24, 1957 (age 67)
Friedrichshafen, West Germany
Occupation(s)Molecular biologist, Immunologist, Entrepreneur and professor
Years active1986-present

Patrick Baeuerle (born 24 November 1957) is a German-based molecular biologist, immunologist, professor and a biopharmaceutical entrepreneur. Baeuerle is known for his work on tyrosine sulfation of proteins,[1] transcription factor NF-kappaB,[2] and the development of bispecific T-cell engaging antibodies for therapy of cancer.[3]

Education

[edit]

Baeuerle earned his diploma in biology from University of Konstanz, Germany. He received his Ph.D. in biochemistry summa cum laude, from the Ludwig Maximilian University of Munich. His postdoctoral training was with the Nobel Laureate David Baltimore at the Whitehead Institute at Massachusetts Institute of Technology, Cambridge, MA.[4][5]

Career

[edit]

After his post-doctorate, Baeuerle led a research group at Gene Center in Martinsried, Germany. In 1993, he became the professor of molecular biology, and was and the chairman at the medical faculty of Freiburg University, Germany.[6]

Between 1996 and 2015, he served as head of drug discovery at Tularik Inc.,[7][8] as chief scientific officer at Micromet Inc.,[9][10] and as a vice president research for Amgen Inc.[11] in Munich, Germany.

Baeuerle is the co-founder of the companies, iOmx AG, Harpoon Inc,[12] TCR2 Inc,[10] Maverick Inc, and Cullinan LLC. He is one of the Managing directors at MPM capital, which is a Cambridge-based venture capital firm.[11][13]

Research Activities

[edit]

Tyrosine Sulfation

[edit]

In 1987, Baeuerle showed that tyrosine sulfation is a frequent modification of secretory proteins that is added in the trans-Golgi compartment.[14][1]

Transcription factor NF-kappaB

[edit]

Baeuerle deciphered the canonical pathway by which transcription factor NF-kappaB is activated and first described inhibitory subunit I-kappaB and the p65/RelA subunit.[2][15] Baeuerle is said to be one of the inventors of the controversial NF-kappaB.[16][17] He along with his team showed that NF-kappaB is an oxidative stress-responsive transcription factor and described a functional role of NF-kappaB in the nervous system.[18][19]

Cancer Therapy

[edit]

Baeuerle lead the development of BiTE antibody Blincyto® (blinatumomab; AMG 103)[20] which is approved by the US FDA for treatment of relapsed/refractory acute lymphoblastic leukemia.[21][22] He has invented various antibody-based constructs that are designed to engage cytotoxic T cells for lysis of cancer cells.[23]

References

[edit]
  1. ^ a b Baeuerle, P A; Huttner, W B (1 December 1987). "Tyrosine sulfation is a trans-Golgi-specific protein modification". Journal of Cell Biology. 105 (6): 2655–2664. doi:10.1083/jcb.105.6.2655. PMC 2114704. PMID 3121635.
  2. ^ a b Baeuerle, P A; Henkel, T (April 1994). "Function and Activation of NF-kappaB in the Immune System". Annual Review of Immunology. 12 (1): 141–179. doi:10.1146/annurev.iy.12.040194.001041. PMID 8011280.
  3. ^ Baeuerle, Patrick A.; Reinhardt, Carsten (15 June 2009). "Bispecific T-Cell Engaging Antibodies for Cancer Therapy". Cancer Research. 69 (12): 4941–4944. doi:10.1158/0008-5472.CAN-09-0547. PMID 19509221.
  4. ^ WO 1989008147, Patrick A. Baeuerle, David Baltimore, Whitehead Institute For Biomedical Research, "ACTIVITION OF NF-kB PRECURSOR", published 1989-03-01 
  5. ^ Baeuerle, Patrick A.; Baltimore, David (April 1988). "Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-κB transcription factor". Cell. 53 (2): 211–217. doi:10.1016/0092-8674(88)90382-0. PMID 3129195. S2CID 24771542.
  6. ^ Hall, Stephen S. (23 November 1997). "Success Is Like a Drug". The New York Times.
  7. ^ "Two Distinct Career Paths Offer Clear Choices". The Scientist. Retrieved 2017-10-04.
  8. ^ "Reinventing the Antibody". The Scientist. Retrieved 2017-10-04.
  9. ^ Perkel, Jeffrey (14 August 2008). "New Lymphoma Drug Shows Promise". Washington Post.
  10. ^ a b "TCR2 Therapeutics Unveils New Cancer Therapy Approach and $44.5M Round | Xconomy". Xconomy. 2016-12-08. Retrieved 2017-10-04.
  11. ^ a b "Amgen vet Patrick Baeuerle inspires a $45M round from A-list VCs for a next-gen I/O drug platform". endpts.com. Retrieved 2017-10-04.
  12. ^ Gormley, Brian (25 May 2017). "Harpoon Therapeutics Snares $45 Million Series B for Prostate Cancer Treatment". WSJ.
  13. ^ "MPM Names Drug Developer Patrick Baeuerle Managing Director". Wall Street Journal. 13 March 2015.
  14. ^ "Tyrosine sulfation of yolk proteins 1, 2, and 3 in Drosophila melanogaster (PDF Download Available)". ResearchGate. Retrieved 2017-10-04.
  15. ^ Baeuerle, Patrick A.; Baltimore, David (28 October 1988). "IκB: a Specific Inhibitor of the NF-κB Transcription Factor". Science. 242 (4878): 540–546. Bibcode:1988Sci...242..540B. doi:10.1126/science.3140380. PMID 3140380. ProQuest 213535026.
  16. ^ US 6410516, Baltimore, David; Sen, Ranjan & Sharp, Phillip A., "Nuclear factors associated with transcriptional regulation", published Jun 25, 2002 
  17. ^ "Espacenet - Bibliographic data". worldwide.espacenet.com. Retrieved 2017-10-04.
  18. ^ "Patrick A. Baeuerle - Google Scholar Citations". scholar.google.de. Retrieved 2017-10-04.
  19. ^ Schreck, Ralf; Albermann, Kaj; Baeuerle, Patrick A. (January 1992). "Nuclear Factor Kb: An Oxidative Stress-Responsive Transcription Factor of Eukaryotic Cells (A Review)". Free Radical Research Communications. 17 (4): 221–237. doi:10.3109/10715769209079515. PMID 1473734.
  20. ^ Baeuerle, Patrick A.; Kufer, Peter; Bargou, Ralf (February 2009). "BiTE: Teaching antibodies to engage T-cells for cancer therapy". Current Opinion in Molecular Therapeutics. 11 (1): 22–30. PMID 19169956.
  21. ^ Swaminathan, Nikhil (15 August 2008). "Antibody Drug Unleashes Tumor-Killer T Cells". Scientific American.
  22. ^ Highfield, Roger (14 August 2008). "Patients 'free from cancer' after immune-boost treatment". The Telegraph.
  23. ^ Baeuerle, Patrick A.; Reinhardt, Carsten (15 June 2009). "Bispecific T-Cell Engaging Antibodies for Cancer Therapy". Cancer Research. 69 (12): 4941–4944. doi:10.1158/0008-5472.CAN-09-0547. PMID 19509221.
[edit]
  1. University of Munich
  2. Micromet, Inc.
  3. University of Konstanz
  4. Max-Planck Institute of Molecular Cell Biology and Genetics
  5. Max-Planck Institute for Neurobiology
  6. EMBL
  7. Whitehead Institute
  8. GeneCentre
  9. University of Freiburg
  10. NF-kappa B (516) patent
Retrieved from "https://wiki.riteme.site/w/index.php?title=Patrick_A._Baeuerle&oldid=1226336176"